Business Wire

U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV

Del

Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved updated labeling for Epclusa® (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV. Epclusa received regulatory approval for the treatment of adults with genotype 1-6 chronic HCV infection without cirrhosis or with compensated cirrhosis, or with decompensated cirrhosis in combination with ribavirin, in the United States on June 28, 2016.

Epclusa has a boxed warning in its product label regarding the risk of hepatitis B virus (HBV) reactivation in HCV/HBV co-infected patients. See below for important safety information.

“HCV co-infection remains a major cause of morbidity in HIV-infected individuals. With this expanded use, Epclusa provides co-infected patients with a much needed one-pill-a-day regimen that works across all HCV genotypes and is compatible with widely-used antiretroviral regimens,” said David Wyles, M.D., Chief, Division of Infectious Disease, Denver Health Medical Center; Associate Professor of Medicine, University of Colorado School of Medicine. “With Epclusa, physicians have an important new treatment option for their HCV/HIV co-infected patients.”

The supplemental new drug application (sNDA) was supported by data from the open-label, Phase 3 ASTRAL-5 study, which evaluated 12 weeks of treatment with Epclusa in 106 subjects with genotype 1-4 HCV infection who were co-infected with HIV and on stable antiretroviral therapy. In the study, 95 percent (101/106) of patients achieved the primary endpoint of SVR12, defined as an undetectable viral load 12 weeks after completing therapy.

The safety profile of Epclusa in HCV/HIV co-infected patients was similar to that observed in HCV mono-infected patients. The most common adverse events (in at least 10 percent of subjects) were fatigue (22 percent) and headache (10 percent).

“Epclusa has already helped further simplify HCV treatment among mono-infected patients, and we are pleased that HCV/HIV co-infected patients can benefit from this pan-genotypic single tablet regimen,” said John F. Milligan, PhD, Gilead’s President and Chief Executive Officer. “This approval advances the commitment we’ve made to the HCV and HIV communities to deliver innovative new treatments that address their unmet medical needs.”

U.S. Patient Support Program

To support these patients and their families, Gilead’s U.S. Support Path® program provides information regarding access and reimbursement coverage options to patients in the United States who need assistance with coverage for their medications, including Epclusa. Support Path conducts benefits investigations and provides patients with information regarding their insurance options.

Further, the Epclusa Co-pay Coupon Program offers co-pay assistance for eligible patients with private insurance who need assistance paying for out-of-pocket medication costs.

To learn more about Support Path for Epclusa, please visit www.MySupportPath.com or call 1-855-7-MYPATH (1-855-769-7284) between 9:00 a.m. and 8:00 p.m. (Eastern), Monday through Friday.

Global Availability

The prevalence of HCV genotypes varies regionally throughout the world. In resource-limited settings genotype testing can often be costly or unreliable, posing yet another barrier to treatment. As a pan-genotypic therapeutic option, Epclusa may help eliminate the need for genotype testing and has the potential to accelerate access to treatment for patients worldwide.

Gilead is committed to helping enable access to Epclusa around the world. Gilead works with a network of regional business partners, generic licensing partners and other stakeholders to expand treatment globally. Epclusa is already licensed to Gilead’s 11 Indian manufacturing partners who produce and distribute generic versions of this medicine for 101 developing countries.

Important U.S. Safety Information for Epclusa

BOXED WARNING: RISK OF HEPATITIS B VIRUS REACTIVATION IN HCV/HBV CO-INFECTED PATIENTS

Test all patients for evidence of current or prior hepatitis B virus (HBV) infection before initiating treatment with Epclusa. HBV reactivation has been reported in HCV/HBV co-infected patients who were undergoing or had completed treatment with HCV direct acting antivirals (DAAs) and were not receiving HBV antiviral therapy. Some cases have resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in patients who are HBsAg positive, in patients with serologic evidence of resolved HBV, and also in patients receiving certain immunosuppressant or chemotherapeutic agents; the risk of HBV reactivation associated with treatment with HCV DAAs may be increased in patients taking these other agents. Monitor HCV/HBV co-infected patients for hepatitis flare or HBV reactivation during HCV treatment and post-treatment follow-up. Initiate appropriate patient management for HBV infection as clinically indicated.

Contraindications

  • If Epclusa is used in combination with ribavirin (RBV), all contraindications, warnings and precautions, in particular pregnancy avoidance, and adverse reactions to RBV also apply. Refer to RBV prescribing information.

Warnings and Precautions

  • Serious Symptomatic Bradycardia When Coadministered with Amiodarone: Amiodarone is not recommended for use with Epclusa due to the risk of symptomatic bradycardia, particularly in patients also taking beta blockers or with underlying cardiac comorbidities and/or with advanced liver disease. A fatal cardiac arrest was reported in a patient taking amiodarone who was coadministered a sofosbuvir containing regimen. In patients without alternative, viable treatment options, cardiac monitoring is recommended. Patients should seek immediate medical evaluation if they develop signs or symptoms of bradycardia.
  • Risk of Reduced Therapeutic Effect Due to Concomitant Use of Epclusa with P-gp Inducers and/or Moderate to Potent Inducers of CYP2B6, CYP2C8 or CYP3A4: Rifampin, St. John’s wort, and carbamazepine are not recommended for use with Epclusa as they may significantly decrease sofosbuvir and/or velpatasvir plasma concentrations.

Adverse Reactions

  • The most common adverse reactions (≥10%, all grades) with Epclusa were headache and fatigue; and when used with RBV in decompensated cirrhotics were fatigue, anemia, nausea, headache, insomnia, and diarrhea.

Drug Interactions

  • Coadministration of Epclusa is not recommended with topotecan due to increased concentrations of topotecan.
  • Coadministration of Epclusa is not recommended with proton-pump inhibitors, oxcarbazepine, phenobarbital, phenytoin, rifabutin, rifapentine, efavirenz, and tipranavir/ritonavir due to decreased concentrations of sofosbuvir and/or velpatasvir.

Consult the full Prescribing Information for Epclusa for more information on potentially significant drug interactions, including clinical comments.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company’s mission is to advance the care of patients suffering from life-threatening diseases. Gilead has operations in more than 30 countries worldwide, with headquarters in Foster City, California.

Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including the risk that physicians may not see the benefits of prescribing Epclusa for the treatment of adults with chronic HCV infection, for expanded use in patients co-infected with HIV. These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements. The reader is cautioned not to rely on these forward-looking statements. These and other risks are described in detail in Gilead’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2017, as filed with the U.S. Securities and Exchange Commission. All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

U.S. Full Prescribing Information for Epclusa, including BOXED WARNING, is available at www.gilead.com .

Epclusa is a registered trademark of Gilead Sciences, Inc., or its related companies.

For more information on Gilead Sciences, please visit the company’s website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Contact information

Gilead Sciences, Inc.
Investors:
Sung Lee, 650-524-7792
or
Media:
Mark Snyder, 650-522-6167

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

GSMA and AIC Encourage Greater Engagement among RCEP Countries to Enable a Truly Pan-Asian Digital Economy18.10.2017 07:00Pressemelding

The GSMA and the Asia Internet Coalition (AIC) today urged the participating countries of the Regional Comprehensive Economic Partnership (RCEP) for greater commitment and engagement. As representatives of leading companies that operate in the region and promote the digital economy, the GSMA and AIC believe that the RCEP can play a critical role in enabling positive policy development in the digital economy and reducing or removing barriers and restrictions that suppress digital trade and investments in the Asia Pacific region. “The RCEP will play an increasingly important role in the region’s digital future, as it involves all of the largest Asian economies, including both ASEAN and non-ASEAN nations,” said Alasdair Grant, head of Asia Pacific for the GSMA. “This is even more critical in light of the stalled talks on the Trans-Pacific Partnership, as well as the growing need for innov

Utimaco Launches PaymentServer 3.00.0 To Help Payment Industry Reach PCI Compliance18.10.2017 06:11Pressemelding

As the Payment Card Industry (PCI) continues to heat up, Utimaco is providing enterprises in the banking and financial services sector with the opportunity to achieve PCI compliance through its latest launch, PaymentServer 3.00.0. The new PaymentServer is a PCI Standards Security Council accredited PCI PIN Transaction Security Hardware Security Module Version 2 (PCI PTS HSM V2) solution that comes with a complete offering, including the HSM, a Software Development Kit, and additional services such as integration support, certification assistance and tiered maintenance. All of this allows Utimaco partners to focus on business innovation with the assurance that their work remains or regains PCI compliance. Using Utimaco’s flexible software development kit, companies can reach full PCI compliance for a solution or environment based on the standard product offering from PaymentServer or vi

The Body Shop Switzerland Transforms the Shopping Experience with Axway18.10.2017 06:00Pressemelding

The Body Shop, an international beauty business, is leveraging Axway (Paris:AXW) (Euronext: AXW.PA), a catalyst for digital transformation, to improve the customer experience at retail stores throughout Switzerland. With Axway Appcelerator, The Body Shop has been able to rethink its customer loyalty program, integrate massive amounts of data, and successfully implement an innovative new mobile application to increase in-store purchases. The new Axway-powered Love Your Body Club mobile app has enabled The Body Shop to deliver personalized and contextualized experience to more than 90,000 customers in Switzerland. Formed in 1976, The Body Shop is an international, ethical beauty business that sells more than 900 different beauty products in 2,600 stores worldwide and online. To build on its successful business in Switzerland and enhance the experience it offers to customers in the

Norsk Titanium Dedicates Plattsburgh Machines at Ceremony with New York Governor18.10.2017 06:00Pressemelding

Norsk Titanium (Norsk), the world’s first FAA-approved supplier of aerospace-grade, additive manufactured, structural titanium components, held a dedication ceremony yesterday of its Plattsburgh Development and Qualification Center (PDQC) in Plattsburgh, New York. This facility, which currently houses nine of Norsk’s proprietary Rapid Plasma DepositionTM (RPD) titanium printing machines, signifies the partnership between Norsk and the state of New York. The site will produce aerospace components for Boeing and other aerospace producers. State and local officials, including New York Governor Andrew Cuomo, Howard Zemsky of Empire State Development, Michael Cashman of the Town of Plattsburgh, the City of Plattsburgh Mayor Colin Reed and Garry Douglas of the North Country Chamber of Commerce participated in the ceremony. "Norsk could have chosen anywhere in the nation to set up their

SailPoint Propels the Identity-Aware Enterprise with New Version of IdentityIQTM18.10.2017 05:01Pressemelding

From Navigate ’17, SailPoint, the leader in enterprise identity management, today announced several enhancements to its open identity platform, designed to further enable identity to be woven throughout the IT operations and security fabric of global organizations. Now, critical identity governance processes, such as separation-of-duty policies and access request approvals, can be leveraged as a shared service within solutions that help support an identity-aware ecosystem. This accelerates the time it takes to get visibility into and control over crucial resources, while also enabling a unified approach to identity governance that shares identity context across all IT and security investments. With an identity-aware IT ecosystem, customers are better prepared to mitigate, identify and contain data breaches. The latest iteration of SailPoint’s IdentityIQ, which i

SailPoint Brings the Power of Identity to Navigate ’17 in Europe18.10.2017 05:01Pressemelding

SailPoint, the leader in enterprise identity management, today welcomed European customers, prospects and partners to Navigate ’17 in Amsterdam. Navigate is the company’s annual identity governance conference, and this year’s packed agenda includes a keynote address from award-winning writer and broadcaster Misha Glenny, whose expertise focuses on cybersecurity, global organized crime and international relations. Conference attendees will also hear from SailPoint customers including ABN AMRO, G-Research, NXP Semiconductors and Skandia about how the power of identity has enabled their businesses. As a new addition to Navigate ’17, SailPoint is honoring customers that exemplify the company’s core values, which are integral to the company’s success and by extension, its customers. These awards highlight customers that are pushing the boundaries of identity governance for the

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom